[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@DrRishabhOnco Avatar @DrRishabhOnco Dr Rishabh Jain

Dr Rishabh Jain posts on X about spacex, india, target, new england the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence countries travel destinations celebrities finance technology brands currencies

Social topic influence spacex #215, india, target, new england #297, status, the modern, met, locks, median, jto

Top accounts mentioned or mentioned by @oncoalert @myesmo @asco @esmoopen @elonmusk @jcoasco @dfcibreastonc @nejm @erictopol @iaslc @thelancetoncol @jamaonc @sabcssanantonio @annalsoncology @jamacurrent @oncbrothers @stolaney1 @mirrorsmed @vincentrk @larvol

Top Social Posts

Top posts by engagements in the last XX hours

"The "Wild West" of post-CDK4/6i HR+/HER2- mBC is finally getting a map. 🗺 We are moving from empiric sequencing to precision flowcharts. 🔑 Key Pivot: Your 2L choice now depends entirely on ESR1 and PI3K/AKT/PTEN status. Here is the modern treatment algorithm #SABCS25 #bcsm @OncoAlert"
X Link 2025-12-10T04:28Z 4976 followers, 6237 engagements

"@JM_Scindia @LaurenDreyer @Starlink @narendramodi @SpaceX @PMOIndia @PIB_India Jio was upgrade. Starlink would be leap. 🌍"
X Link 2025-12-10T14:13Z 4976 followers, 14.4K engagements

"BREAKING - First Oral SERD Shows Benefit in Early Breast Cancer Roches giredestrant becomes the first-ever oral SERD to demonstrate superior invasive DFS vs standard endocrine therapy in early ER+/HER2- breast cancer 🔥 🧬 lidERA Phase III (n 4100) Medium/high-risk Stage I-III ER+/HER2- Adjuvant setting Met primary endpoint at interim Statistically significant & clinically meaningful iDFS benefit Favourable safety profile OS immature but trending positive 🌟 Why this matters ER+ accounts for XX percent of all breast cancers. Up to one-third still recur despite current endocrine therapy."
X Link 2025-11-18T15:25Z 4946 followers, 2634 engagements

"🔥 Why are CAR-T cells called CHIMERIC Because theyre the Marvel-style fusion superheroes of Immunotherapy 💥🧬** CAR-T cells arent born Theyre built - piece by piece by fusing powers from different immune systems. Thats what makes them chimeric. Imagine assembling the ultimate cancer-killing Avenger: 🦾 Antibody Head (Iron Mans targeting system) Locks onto tumor antigens with laser precision. ⚡ T-cell Body (Thors hammer) Executes the kill with raw cytotoxic force. 🔌 Co-stimulatory Boosters (Captain Americas serum) Gives endurance persistence and unstoppable expansion. 🎯 CD3 Signaling"
X Link 2025-11-28T14:05Z 4935 followers, 9823 engagements

"🔥 New KRAS G12C combo making noise in NSCLC Olomorasib + Pembrolizumab hits XX% ORR in PD-L1 XX% first-line patients 🤯 (Phase 1b LOXO-RAS-20001 JTO) 🧬 Why this matters Past KRAS G12C + IO combos = hepatotoxicity nightmares 😬 Olomorasib is next-gen ultra-selective better tolerability + deeper target occupancy. 📊 Key Results X Overall (n=91) ORR: XX% DCR: XX% Median DOR: XXXX mo Median PFS: XXXX mo X First-line (n=46) ORR: XXXX% 12-mo PFS: XXXX% Median DOR/PFS: NR X PD-L1 XX% first-line (n=20) 🔥 ORR: XX% Responses across PD-L1 50100% 🛡 Safety Grade X TRAEs: XX% Common: diarrhea (34%) ALT"
X Link 2025-11-30T06:07Z 4946 followers, 4065 engagements

"@realHaazzed I dont think its currently made for that. Its purpose is to read papers more efficiently"
X Link 2025-12-09T15:43Z 4945 followers, XX engagements

"APOLLO trial confirms ATRAATO use for patients with highrisk APL - Lawrence - 2025 - Cancer - Wiley Online Library"
X Link 2025-12-05T15:48Z 4975 followers, 1140 engagements

"🚨 St Gallen 2025: Evidence-backed upgrades in early breast cancer A consensus now aligned with KEYNOTE-522 TAILORx SOUND INSEMA KATHERINE and OlympiA. 1) Genetics & Prevention 🧬 BRCA1/2 PALB2 strong support for contralateral risk-reducing surgery. 📌 Evidence: OlympiA TBCRC XXX. 2) DCIS 🟦 BCS + RT remains standard; endocrine therapy for ER+. ⛔ Active monitoring not yet routine. 📌 Evidence: COMET. 3) Breast Surgery 🔪 BCS preferred even for selected multifocal cases. 📌 Evidence: NSABP B-06 ACOSOG Z11102. 4) Axilla De-escalation 🟩 SLNB omission allowed in postmenopausal ER+ T1"
X Link 2025-12-08T14:18Z 4975 followers, 9225 engagements

"@JM_Scindia @LaurenDreyer @Starlink @narendramodi @SpaceX @PMOIndia @PIB_India Hope lobbying does not stop this. India deserves tech that reaches every village not just every tower. 📡"
X Link 2025-12-10T14:14Z 4976 followers, 59.4K engagements

"@SpaceX Access to space is not just a journey upward. It is a shift in how we see ourselves. Explorers not inhabitants"
X Link 2025-12-11T07:35Z 4976 followers, XX engagements

"🚨 ONCO EMERGENCY: How to Manage EXTRAVASATION in XX Seconds 🩺💉 Extravasation of chemotherapy = oncology emergency. Early recognition + immediate action = tissue saved. Heres the crisp protocol-ready approach 👇 X STOP Immediately ❌ Stop infusion ❌ Do not flush ✔ Leave cannula in situ ✔ Aspirate as much drug as possible ✔ Mark the area + click a photo X Identify the Agent Classify the drug: 🔥 Vesicant (DNA-binding / Non-DNA) 😣 Irritant 🙂 Non-vesicant (Anthracyclines Vinca alkaloids Taxanes Platinum Mitomycin etc.) X Two Key Pathways A) Localise & Neutralise DNA-Binding Vesicants"
X Link 2025-11-25T12:51Z 4962 followers, 40.2K engagements

"🚨 NEW FDA APPROVAL: Durvalumab in Resectable Gastric/GEJ Cancer 🎯 Perioperative immunotherapy enters gastric cancer FDA has approved Durvalumab + FLOT (neoadjuvant surgery adjuvant durva) for resectable gastric/GEJ adenocarcinoma. 🔬 Backed by Phase III MATTERHORN (NCT04592913): 📉 XX% reduction in risk of progression recurrence or death 🎉 pCR: XXXX% vs XXX% with FLOT alone Median EFS not reached vs XXXX mo 🔐 Benefit consistent across key subgroups 💊 Regimen Neoadjuvant: Durva + FLOT (4 cycles) Surgery Adjuvant: Durva for XX cycles 🛡 Safety: Expected immune-AEs; manageable; no new"
X Link 2025-11-26T04:00Z 4974 followers, 8657 engagements

"NECTIN4 is not one story. It is three different diseases hiding under one biomarker 📌 #GlobalForum25 #BLADDR25 🧬 X. Amplification = the super responder biology Tumors with NECTIN4 amplification show ORR XX percent with EV vs XX percent without. OS and PFS curves split early and stay apart. FISH + IHC on metastases unlocks this group. 🧩 X. Loss = the broken door handle Metastases lose membranous NECTIN4 in XX percent cases. Low H score (0 to 99) links to EV resistance and shorter PFS. RNA alone is unreliable. Protein matters. 🌍 X. Metastasis biology = the real tumor Primary and metastatic"
X Link 2025-12-04T19:35Z 4974 followers, 4239 engagements

"ATRA + ATO becomes the new standard for high-risk APL 🔥 The phase X APOLLO trial tested whether the success of ATRAATO in standard risk APL can extend to high-risk APL. 🧩 Design: XXX newly diagnosed high-risk APL patients Randomized 1:1 Arm A: ATRA + ATO Arm B: ATRA + anthracycline-based chemotherapy Primary endpoint: 2-year EFS Median follow-up: X years 📊 Key results: 🧪 2-year EFS: XX% vs XX% 📉 HR: XXX 🧬 Molecular relapse: XXX% vs XXXX% 💊 Serious AEs: XX% vs XX% Takeaway: ATRAATO should be the preferred frontline therapy for all newly diagnosed APL. 📖 Full paper in comment @OncoAlert"
X Link 2025-12-05T15:47Z 4974 followers, 2276 engagements

"Doublet vs Triplet in mHSPC: Fast Takeaways 🔍 #GlobalForum25 #PROSCA25 🧬 ADT + ARPI = SOC Intensify only when biology or volume demands it. 💥 Doublet enough 😊 Metachronous low volume 😊 Elderly low volume 😊 Low risk biology 👉 ADT + ARPI 🔥 Biology driven intensification 🚨 TP53 or RB1 loss 🚨 PTEN loss 🚨 BRCA or HRR mutations 👉 Add docetaxel 💜 Clear Triplet candidates ⚡ De novo high volume ⚡ AR independent or high proliferative biology 👉 Triplet gives strongest OS effect 🌫 Avoid intensification 🧓 Frail or comorbid 👉 ADT alone or ARPI if tolerated New Triplets 🟦 AMPLITUDE:"
X Link 2025-12-05T18:07Z 4973 followers, 8226 engagements

"Before trusting any NGS report ask this: how deep was it sequenced and how much tumour was actually there 🔍🧬 #GlobalForum25 #PROSCA25 🧬 Coverage matters Higher depth increases detection of SNVs indels and CNVs. FFPE somatic ideally needs x500 to x1000 intended coverage for reliable calls. 🎯 Region coverage vs target coverage Region coverage = which genome sections you decide to read. Target coverage = how intensely you read those sections. 🧪 Mean coverage thresholds Minimum reliable threshold x200 but FFPE ideally approaches x500 to avoid false negatives. Any region below threshold"
X Link 2025-12-06T14:47Z 4974 followers, 6224 engagements

"🧬 Universal base-edited CAR T cells just changed the conversation in T-ALL. NEJM reports a landmark phase X experience with BE-CAR7 in relapsed or refractory T-ALL. What is BE-CAR7 🧪 A universal off-the-shelf CAR T product engineered with triple CT base edits to knock out TCR CD52 and CD7 preventing GVHD fratricide and alemtuzumab sensitivity. What was done 🔧 Patients received BE-CAR7 after fludarabine-cyclophosphamide-alemtuzumab lymphodepletion to achieve deep MRD remission before allo-SCT. Key results 🧒👩 XX treated (9 children X adults) 📉 XXX percent morphologic remission at day 28"
X Link 2025-12-09T09:58Z 4974 followers, 1525 engagements

"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia New England Journal of Medicine"
X Link 2025-12-09T10:00Z 4966 followers, XXX engagements

"@elonmusk @Starlink When connectivity reaches the most remote corners opportunity follows. India plus Starlink might change far more than internet speeds"
X Link 2025-12-10T14:12Z 4963 followers, 3342 engagements

"@vineeshkkv @JM_Scindia @LaurenDreyer @Starlink @narendramodi @SpaceX @PMOIndia @PIB_India They will definitely offer value for money"
X Link 2025-12-10T17:05Z 4979 followers, XXX engagements

"Understanding How Aspirin Prevents Metastasis New England Journal of Medicine"
X Link 2025-12-11T09:25Z 4978 followers, XXX engagements

"Top XX Economies + Current GDP X. USA $28.9T X. China $18.5T X. Germany $4.6T X. Japan $4.2T X. India $4.0T X. UK $3.3T X. France $3.1T X. Italy $2.3T X. Russia $2.2T XX. Canada $2.1T XX. Brazil $2.1T XX. Spain $1.7T XX. Mexico $1.6T XX. South Korea $1.7T XX. Australia $1.6T"
X Link 2025-12-01T11:28Z 4976 followers, 6235 engagements

"RJBC-1501 Trial Update at #SABCS25 Carboplatin continues to surprise in early TNBC. Adding it to EC-T improved every key curve we care about. 🎯 Primary Endpoint: DFS EC-T vs EC-TCb 3-yr DFS XXXX% vs XXXX% 5-yr DFS XXXX% vs XXXX% HR XXXX (95% CI XXXX to 0.97) p = XXXX 🌍 Secondary Endpoints Distant DFS: clear separation of curves Overall Survival: trend favoring EC-TCb 🧩 Subgroup signals (DFS): Benefit consistent across most groups Stronger effect in: Age XX T2 tumors High Ki-67 Node positive 💡 Takeaway Adding carboplatin to an EC-T backbone in stage II-III TNBC delivered meaningful"
X Link 2025-12-10T10:11Z 4976 followers, 2640 engagements

"The HR+ landscape is getting complicated. 🤯 PROTAC vs. CERAN vs. SERD. If you don't know the difference you can't predict the resistance. Your cheat sheet for the next gen ER toolkit is here. Save this for clinics 🔖 #SABCS25. #Oncology #MedTwitter #bcsm @OncoAlert @Larvol @SABCSSanAntonio @ASCO @stolaney1 @PTarantinoMD"
X Link 2025-12-10T13:25Z 4976 followers, 3052 engagements

"🚨 HER2CLIMB XX just made maintenance exciting in HER2+ MBC #SABCS25 Finish THP induction then instead of wait and watch you lock in control with tucatinib plus HP in 1L maintenance. ✨ Big picture 💙 Median PFS: XXXX vs XXXX months 💙 Extra XXX months without progression 💙 HR XXXX (0.51 to 0.79) p XXXXXX 🧬 Works in both HR negative and HR positive 🟦 HR negative PFS XXXX vs XXXX months HR XXXX (0.40 to 0.76) p = XXXXXX +12.3 months gain 🟧 HR positive PFS XXXX vs XXXX months HR XXXX (0.55 to 0.98) p = XXXXXX +6.9 months gain 😌 Toxicity that oncologists can live with Mostly low grade"
X Link 2025-12-10T15:47Z 4975 followers, 1852 engagements

"🔥 A century old drug. A brand new mechanism. Aspirin doesnt just thin blood. It disarms metastasis. 🧬 New NEJM insight: Platelet TXA2 activates ARHGEF1 on T cells switching off antitumor immunity. 💊 Low dose aspirin blocks COX1 suppresses TXA2 T cells stay active metastasis drops. 🥼 Immunogenic tumors like MMRd and PI3K altered CRC may benefit the most. 💡 Cheap. Generic. Mechanistically elegant. The science finally explains what epidemiology saw for decades. 📖 Full paper in comment #OncoTwitter #MedTwitter #CancerResearch @OncoAlert @myesmo @esmo_open @asco @NEJM"
X Link 2025-12-11T09:24Z 4976 followers, XXX engagements

"🌸 Aromatase Inhibitor quietly wins the decade. #SABCS25 Ten year ALTT0 exploratory follow up clarifies endocrine therapy in HR+/HER2+ early breast cancer. 📈 Efficacy AI vs SERM showed clear long term gains in: DFS XXXX percent vs XXXX percent (aHR XXXX CI XXXX to 0.82) TTDR XXXX percent vs XXXX percent (aHR XXXX CI XXXX to 0.85) 💗 Survival OS remained identical XXXX percent vs XXXX percent (aHR XXXX CI XXXX to 1.00) 👩⚕ Across Menopausal Groups Premenopausal: AI OFS SERM OFS Postmenopausal: AI SERM Benefit was consistent across curves and subgroup tables. 🎯 Clinical Takeaway For HR+/HER2+"
X Link 2025-12-11T09:31Z 4976 followers, 1232 engagements

"The Oral SERD pipeline is crowded. Here is your cheat sheet. 📝 #SABCS2025 Its not just about Metastatic anymore. The battleground is moving to Adjuvant: ⚔ lidERA (Giredestrant) ⚔ EMBER-4 (Imlunestrant) ⚔ CAMBRIA (Camizestrant) Will adjuvant SERDs replace AIs That's the billion-dollar question. @OncoAlert @SABCSSanAntonio"
X Link 2025-12-10T04:37Z 4975 followers, 5228 engagements

"🧠💊 #SABCS25 Can we delay brain mets in HR+/HER2+ MBC #PATINA shows that adding palbociclib to anti-HER2 + endocrine therapy reduces CNS events 📉 🧬 Trial: PATINA phase III 👥 HR+/HER2+ metastatic breast cancer ⚖ Arms ➕ ➡ Palbociclib + trastuzumab + pertuzumab + ET ➡ Trastuzumab + pertuzumab + ET 📊 Key CNS outcome At XX months 🧠 CNS progression or death 👉 XXXX% with palbociclib 👉 XXXX% with control 📉 Absolute reduction X% P = XXXXXX 📈 Primary PFS mPFS XXXX vs XXXX months HR XXXX ✔ 💡 Why it matters Beyond systemic control palbociclib may delay or prevent CNS involvement in HR+/HER2+"
X Link 2025-12-12T05:29Z 4976 followers, XXX engagements